ANCA-associated vasculitides: Pathogenetic aspects and current evidence-based therapy

Journal of Autoimmunity

Volumn 32, Issue 3-4, 2009, Pages 163-171

  Holle, J U ^a   Gross, W L ^a  

^a UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

Author keywords

ANCA associated vasculitis; EULAR recommendations; Evidence based therapy; Wegener's granulomatosis

Indexed keywords

15 DEOXYSPERGUALIN; ABATACEPT; AZATHIOPRINE; BELIMUMAB; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; EPRATUZUMAB; ETANERCEPT; GLUCOCORTICOID; IMMUNOGLOBULIN; INFLIXIMAB; INTERFERON; LEFLUNOMIDE; MEPOLIZUMAB; METHOTREXATE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; MYELOBLASTIN; OCRELIZUMAB; OFATUMUMAB; PREDNISOLONE; PSEUDOMONIC ACID; RITUXIMAB; THYMOCYTE ANTIBODY; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ADAPTIVE IMMUNITY; ANCA ASSOCIATED VASCULITIS; ANEMIA; ARTICLE; BLADDER CARCINOMA; BLADDER DISEASE; BRONCHOPNEUMONIA; CHURG STRAUSS SYNDROME; CLINICAL FEATURE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; DENDRITIC CELL; DISEASE COURSE; DOSE RESPONSE; DRUG DOSE INCREASE; DRUG DOSE REGIMEN; DRUG EFFICACY; EVIDENCE BASED PRACTICE; HEMORRHAGIC CYSTITIS; HUMAN; HYPEREOSINOPHILIC SYNDROME; INFECTION; KIDNEY FAILURE; LEUKOENCEPHALOPATHY; LEUKOPENIA; LIVER TOXICITY; MAINTENANCE THERAPY; MICROSCOPIC POLYANGIITIS; MONOTHERAPY; MULTIPLE ORGAN FAILURE; NEPHROTOXICITY; NONHUMAN; PLASMAPHERESIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECOMMENDED DRUG DOSE; RELAPSE; REMISSION; SERUM SICKNESS; TREATMENT OUTCOME; TREATMENT PLANNING; WEGENER GRANULOMATOSIS;

ANIMALS; ANTIBODIES, ANTINEUTROPHIL CYTOPLASMIC; ANTIBODIES, MONOCLONAL; CYCLOPHOSPHAMIDE; ENZYME INHIBITORS; EVIDENCE-BASED MEDICINE; HUMANS; IMMUNOLOGIC FACTORS; IMMUNOSUPPRESSIVE AGENTS; REMISSION INDUCTION; TUMOR NECROSIS FACTOR-ALPHA; VASCULITIS;

EID: 67349214603     PISSN: 08968411     EISSN: 10959157     Source Type: Journal    
DOI: 10.1016/j.jaut.2009.02.019     Document Type: Article

References (110)

1. Reinhold-Keller E., Beuge N., Latza U., de Groot K., Rudert H., Nolle B., et al. An interdisciplinary approach to the care of patients with Wegener's granulomatosis: long-term outcome in 155 patients. Arthritis Rheum 43 5 (2000 May) 1021-1032
2. Sablé-Fourtassou R., Cohen P., Mahr A., Pagnoux C., Mouthon L., Jayne D., et al. Antineutrophil cytoplasmic antibodies and the Churg-Strauss syndrome. Ann Intern Med 143 (2005) 632-638
3. Guillvevin L., Durand-Gasselin B., Cevallos R., Gayraud M., Lhote F., Callard P., et al. Microscopic polyangiitis: clinical and laboratory findings in eighty five patients. Arthritis Rheum 42 (1999) 421-430
4. Cohen Taervert J.W., van der Woude F.J., Fauci A.S., Ambrus J.L., Velosa J., Keane W.F., et al. Association between active Wegener's granulomatosis and anticytoplasmic antibodies. Arch Intern Med 149 (1989) 2461-2465
5. Finkielman J.D., Merkel P.A., Schroeder D., Hoffman G.S., Spiera R., St Clair E.W., et al., WGET Research Group. Antiproteinase 3 antineutrophil cytoplasmic antibodies and disease activity in Wegener granulomatosis. Ann Intern Med 147 (2007) 611-619
6. Cohen Taervert J.W., Huitema M.G., Hené R.J., Sluiter W.J., The T.H., van der Hem G.K., et al. Prevention of relapses in Wegener's granulomatosis by treatment based on antineutrophil cytoplasmic antibody titre. Lancet 336 (1990) 709-711
7. Kallenberg C.G. Pathogenesis of PR3-ANCA associated vasculitis. J Autoimmun 30 (2008) 29-36
8. Keogh K.A., Ytterberg S.R., Fervenza F.C., Carlson K.A., Schroeder D.R., and Specks U. Rituximab for refractory Wegener's granulomatosis: report of a prospective, open-label pilot trial. Am J Respir Crit Care Med 173 (2006) 180-187
9. Falk R.J., Terrell R.S., Charles L.A., and Jennette J.C. Anti-neutrophil cytoplasmatic autoantibodies induce neutrophils to degranulate and produce oxygen radicals in vitro. Proc Natl Acad Sci U S A 87 (1990) 4115-4119
10. Calderwood J.M., Williams J.M., Morgan M.D., Nash G.B., and Savage C.O. ANCA induces beta2 integrin and CXC chemokine-dependent neutrophil-endothelial cell interactions that mimic those of highly cytokine-activated endothelium. J Leukoc Biol 77 (2005) 33-43
11. Witko-Sarsat V., Lesavre P., Lopez S., Bessou G., Hieblot C., Prum B., et al. A large subset of neutrophils expressing membrane proteinase 3 is a risk factor for vasculitis and rheumatoid arthritis. J Am Soc Nephrol 10 (1999) 1224-1233
12. Rarok A.A., Stegeman C.A., Limburg P.C., and Kallenberg C.G. Neutrophil membrane expression of proteinase 3 (PR3) is related to relapse in PR3-ANCA-associated vasculitis. J Am Soc Nephrol 13 (2002) 2232-2238
13. Csernok E., Ai M., Gross W.L., Wicklein D., Petersen A., Lindner B., et al. Wegener autoantigen induces maturation of dendritic cells and licenses them for Th1 priming via protease-activated receptor-2 pathway. Blood 107 (2006) 4440-4448
14. Matsumoto T., Kaneko T., Wada H., Kobayashi T., Abe Y., Nobori T., et al. Proteinase 3 expression on neutrophil membranes from patients with infectious disease. Shock 26 (2006) 128-133
15. Choi H.K., Lamprecht P., Nieles J.L., Gross W.L., and Merkel P.A. Subacute bacterial endocarditis with positive cytoplasmatic antineutrophil cytoplasmatic antibodies and anti-proteinase 3 antibodies. Arthritis Rheum 43 (2000) 226-231
16. Stegeman C.A., Taervert J.W., Sluiter W.J., Manson W.L., de Jung P.E., and Kallenberg C.G. Association of chronic nasal carriage of staphylococcus aureus and higher relapse rates in Wegener granulomatosis. Ann Intern Med 120 (1994) 12-17
17. Xiao H., Heeringa P., Hu P., Liu Z., Zhao M., Aratani Y., et al. Antineutrophil cytoplasmatic antibodies specific for myeloperoxidase cause glomerulonephritis and vasculitis in mice. J Clin Invest 110 (2002) 955-963
18. Pfister H., Ollert M., Fröhlich L.F., Quintanilla-Martinez L., Colby T.V., Specks U., et al. Antineutrophil cytoplasmatic autoantibodies against the murine homolog of proteinase 3 (Wegener autoantigen) are pathogenic in vivo. Blood 104 (2004) 1411-1418
19. Kain R., Exner M., Brandes R., Ziebermeyer R., Cunningham D., Alderson C.A., et al. Molecular mimicry in pauci-immune focal necrotizing glomerulonephritis. Nat Med 14 (2008) 1088-1096
20. Jacob L., Lety M.A., Monteiro R.C., Louvard D., and Bach J.F. Pathogenic antibodies in systemic lupus erythematodes: anti-LAMP antibodies. C R Acad Sci III 303 (1986) 193-195
21. Bacon P.A. The spectrum of Wegener's granulomatosis and disease relapse. N Engl J Med 352 (2005) 330-332
22. Voswinkel J., Mueller A., and Lamprecht P. Is PR3-ANCA formation initiated in Wegener's granulomatosis lesions? Granulomas as potential lymphoid tissue maintaining antibody production. Ann N Y Acad Sci 1051 (2005) 12-19
23. Voswinkel J., Mueller A., Kraemer J.A., Lamprecht P., Herlyn K., Holl-Ulrich K., et al. B lymphocyte maturation in Wegener's granulomatosis: a comparative analysis of VH genes from endonasal lesions. Ann Rheum Dis 65 (2006) 859-864
24. Csernok E., Trabandt A., Müller A., Wang G.C., Moosig F., Paulsen J., et al. Cytokine profiles in Wegener's granulomatosis: predominance of type 1 (Th1) in the granulomatous inflammation. Arthritis Rheum 42 (1999) 742-750
25. Fries J.F., Hunder G.G., Bloch D.A., Michel B.A., Arend W.P., Calabrese L.H., et al. The American College of Rheumatology 1990 criteria for the classification of vasculitis. Summary. Arthritis Rheum 33 (1990) 1135-1136
26. Jennette J.C., Falk R.J., Andrassy K., Bacon P.A., Churg J., Gross W.L., et al. Nomenclature of systemic vasculitides. Proposal of an international consensus conference. Arthritis Rheum 37 2 (1994) 187-192
27. Hellmich B., Flossman O., Gross W.L., Bacon P., Cohen-Taervert J.W., Guillevin L., et al. EULAR recommendations for conducting clinical studies and/or clinical trials in systemic vasculitis: focus on anti-neutrophil cytoplasm antibody-associated vasculitis. Ann Rheum Dis 66 (2007) 605-617
28. Mukhtyar C., Guillevin L., Cid M.C., Dasgupta B., de Groot K., Gross W., et al. EULAR recommendations for the management of primary small vessel vasculitis. Ann Rheum Dis 68 (Apr 2009) 310-317
29. Fauci A.S., Haynes B.F., Katz P., and Wolff S.M. Wegener's granulomatosis: prospective clinical and therapeutic experience with 85 patients for 21 years. Ann Intern Med 98 (1983) 76-85
30. Hoffman G.S., Kerr G.S., Leqvitt R.Y., Halbahn C.W., Lebowics R.S., Travis W.D., et al. Wegener's granulomatosis: an analysis of 158 patients. Ann Intern Med 116 (1992) 488-498
31. Adu D., Pall A., Luqmani R.A., Richards N.T., Howie A.J., Emery P., et al. Controlled trial of pulse versus continuous prednisolone and cyclophosphamide in the treatment of systemic vasculitis. QJM 90 6 (1997) 401-409
32. Guillevin L., Cordier J.F., Lhote F., Cohen P., Jarrousse B., Royer I., et al. A prospective, multicenter, randomized trial comparing steroids and pulse cyclophosphamide versus steroids and oral cyclophosphamide in the treatment of generalized Wegener's granulomatosis. Arthritis Rheum 40 12 (1997) 2187-2198
33. Rihova Z., Jancova E., Merta M., Zabka J., Rysava R., Bartunkova J., et al. Daily oral versus pulse intravenous cyclophosphamide in the therapy of ANCA associated vasculitis - preliminary single center experience. Prague Med Rep 105 1 (2004) 64-68
34. de Groot K., Adu D., and Savage C.O. The value of pulse cyclophosphamide in ANCA-associated vasculitis: meta-analysis and critical review. Nephrol Dial Transplant 16 10 (2001) 2018-2027
35. de Groot K., and Jayne D. What is new in the therapy of ANCA-associated vasculitides? Take home messages from the 12th workshop on ANCA and vasculitides. Clin Nephrol 64 (2005) 480-484
36. Hu W., Liu C., Xie H., Chen H., Liu Z., and Li L. Mycophenolate mofetil versus cyclophosphamide for inducing remission of ANCA vasculitis with moderate renal involvement. Nephrol Dial Transplant 23 4 (2008) 1307-1312
37. Mukhtyar C., Flossman O., Hellmich B., Bacon P., Cid M., Cohen-Taervert J.W., et al. Outcomes from studies of antineutrophil cytoplasm antibody associated vasculitis: a systematic review by the European League Against Rheumatism Task Force. Ann Rheum Dis 67 (2008) 1004-1010
38. Jayne D., Rasmussen B., and European Community Systemic Vasculitis Clinical Trials Study Group (ECYSVASTRIAL). Treatment of antineutrophil cytoplasm autoantibody-associated systemic vasculitis: initiatives for the European Community Systemic Vasculitis Clinical Trials Study Group. Mayo Clin Proc 72 (1997) 737-747
39. Hoffman G.S., Leavitt R.Y., Kerr G.S., and Fauci A.S. The treatment of Wegener's granulomatosis with glucocorticoids and methotrexate. Arthritis Rheum 35 (1992) 1322-1329
40. Sneller M.C., Hoffman G.S., Talar-Williams C., Kerr G.S., Halblahn C.W., and Fauci A.S. An analysis of forty-two Wegener's granulomatosis patients treated with methotrexate and prednisone. Arthritis Rheum 38 (1995) 608-613
41. de Groot K., Müller M., Reinhold-Keller E., Paulsen J., and Gross W.L. Induction of remission in Wegener's granulomatosis with low dose methotrexate. J Rheumatol 25 (1998) 492-495
42. Stone J.H., Tun W., and Hellman D.B. Treatment of non-life-threatening Wegener's granulomatosis with methotrexate and daily prednisone as the initial therapy of choice. J Rheumatol 26 (1999) 1134-1139
43. Langford C.A., Talar-Williams C., and Sneller M.C. Use of methotrexate and glucocorticoids in the treatment of Wegener's granulomatosis. Long-term renal outcome in patients with glomerulonephritis. Arthritis Rheum 43 (2000) 1836-1840
44. De Groot K., Rasmussen N., Bacon P.A., Tervaert J.W., Feighery C., Gregorini G., et al. Randomized trial of cyclophosphamide versus methotrexate for induction of remission in early systemic antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 52 8 (2005) 2461-2469
45. Stegeman C.A., Tervaert J.W., de Jong P.E., and Kallenberg C.G. Trimethoprim/sulfamethoxazole (co-trimoxazole) for the prevention of relapses of Wegener's granulomatosis. Dutch Co-Trimoxazole Wegener Study Group. N Engl J Med 335 1 (1996) 16-20
46. Reinhold-Keller E., De Groot K., Rudert H., Nolle B., Heller M., and Gross W.L. Response to trimethoprim/sulfamethoxazole in Wegener's granulomatosis depends on the phase of disease. QJM 89 1 (1996) 15-23
47. de Groot K., Reinhold-Keller E., Tatsis E., Paulsen J., Heller M., Nölle B., et al. Therapy for the maintenance of remission in sixty-five patients with generalized Wegener's granulomatosis. Methotrexate versus trimethoprim/sulfamethoxazole. Arthritis Rheum 39 (1996) 2052-2061
48. Sanders J.S., Huitma M.G., Kallenberg C.G., and Stegeman C.A. Prediction of relapses in PR3-ANCA-associated vasculitis by assessing responses of ANCA titres to treatment. Rheumatology 45 (2006) 724-729
49. Jayne D., Rasmussen N., Andrassy K., Bacon P., Tervaert J.W., Dadoniene J., et al. A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. N Engl J Med 349 1 (2003) 36-44
50. Pagnoux C., Mahr A., Hamidou M.A., Boffa J.J., Ruivard M., Ducroix J.P., et al. Azathioprine or methotrexate maintenance for ANCA-associated vasculitis. N Engl J Med 359 (2008) 2790-2803
51. Metzler C., Miehle N., Manger K., Iking-Koner C., de Groot K., Hellmich B., et al. Elevated relapse rate under oral methotrexate versus leflunomide for maintenance of remission in Wegener's granulomatosis. Rheumatology 46 (2007) 1087-1091
52. Slot M.C., Tervaert J.W., Boosma M.M., and Stegeman C.A. Positive classic antineutrophil cytoplasmatic antibody (C-ANCA) titer at switch to azathioprine therapy associated with relapse in proteinase-3-related vasculitis. Arthritis Rheum 51 (2004) 269-273
53. Langford C.A., Talar-Williams C., Barron K.S., and Sneller M.C. A staged approach to the treatment of Wegener's granulomatosis: induction of remission with glucocorticoids and daily cyclophosphamide switching to methotrexate for remission maintenance. Arthritis Rheum 42 (1999) 2666-2673
54. Reinhold-Keller E., Fink C.O., Herlyn K., Gross W.L., and de Groot K. High rate of relapse in 71 patients with Wegener's granulomatosis under the maintenance of remission with low-dose methotrexate. Arthritis Rheum 47 (2002) 326-332
55. Langford C.A., Talar-Williams C., Barron K.S., and Sneller M.C. Use of a cyclophosphamide-induction methotrexate-maintenance regimen for the treatment of Wegener's granulomatosis: extended follow-up and rate of relapse. Am J Med 114 (2003) 463-469
56. Nowack R., Gobel U., Klooker P., Hergesell O., Andrassy K., and van der Woude F.J. Mycophenolate mofetil for maintenance therapy of Wegener's granulomatosis and microscopic polyangiitis: a pilot study in 11 patients with renal involvement. J Am Soc Nephrol 10 9 (1999) 1965-1971
57. Langford C.A., Talar-Williams C., and Sneller M.C. Mycophenolate mofetil for remission maintenance in the treatment of Wegener's granulomatosis. Arthritis Rheum 51 2 (2004) 278-283
58. Koukoulaki M., and Jayne D.R. Mycophenolate mofetil in anti-neutrophil cytoplasm antibodies-associated systemic vasculitis. Nephron Clin Pract 102 3-4 (2006) c100-c107
59. Lapraik C., Watts R., Bacon P., Carruthers D., Chakravarty K., D`Cruz D., et al. BSR and BHPR guidelines for the management of adults with ANCA associated vasculitis. Rheumatology 46 (2007) 1615-1616
60. Wegener's Granulomatosis Etanercept Trial (WGET) Research Group. Etanercept plus standard therapy for Wegener's granulomatosis. N Engl J Med 352 4 (2005) 351-361
61. Jayne D.R., Gaskin G., Rasmussen N., Abramowicz D., Ferrario F., Guillevin L., et al. Randomized trial of plasma exchange or high-dosage methylprednisolone as adjunctive therapy for severe renal vasculitis. J Am Soc Nephrol 18 7 (2007) 2180-2188
62. Pusey C.D., Rees A.J., Evabs D.J., Peters K.D., and Lockwood C.M. Plasma exchange in focal necrotizing glomerulonephritis without anti-GBM antibodies. Kidney Int 40 4 (1991) 757-763
63. Frasca G.M., Soverinin M.L., Falaschini A., Tampieri E., Vangelista A., and Stefoni S. Plasma exchange treatment improves prognosis of antineutrophil cytoplasmatic antibody-associated crescentic glomerulonephritis: a case-control study in 26 patients from a single center. Therap Apher Dial 7 6 (2003) 540-546
64. Klemmer P.J., Chalermskulrat W., Reif M.S., Hogan S.L., Henke D.C., and Falk R.J. Plasmapheresis therapy for diffuse alveolar hemorrhage in patients with small-vessel vasculitis. Am J Kidney Dis 42 6 (2003) 1149-1153
65. Keogh K.A., Wylam M.E., Stone J.H., and Specks U. Induction of remission by B lymphocyte depletion in eleven patients with refractory antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 52 1 (2005) 262-268
66. Eriksson P. Nine patients with anti-neutrophil cytoplasmic antibody positive vasculitis successfully treated with rituximab. J Intern Med 257 6 (2005) 540-548
67. Stasi R., Stipa E., Del Poeta G., Amadori S., Newland A.C., and Provan D. Longterm observation of patients with anti-neutrophil cytoplasmic antibody-associated vasculitis treated with rituximab. Rheumatology (Oxford) 45 11 (2006) 1432-1436
68. Aries P.M., Hellmich B., Voswinkel J., Both M., Nölle B., Holl-Ulrich K., et al. Lack of efficacy of rituximab in Wegener's granulomatosis with refractory granulomatous manifestations. Ann Rheum Dis 65 7 (2006) 853-858
69. Smith K.G., Jones R.B., Burns S.M., and Jayne D. Long-term comparison of rituximab treatment for refractory systemic lupus erythematodes and vasculitis: remission, relapse and re-treatment. Arthritis Rheum 54 9 (2006) 2970-2982
70. Brihaye B., Aouba A., Pagnoux C., Cohen P., Lacassin F., and Guillevin L. Adjunction of rituximab to steroids and immunosuppressants for refractory/relapsing Wegener's granulomatosis: a study on 8 patients. Clin Exp Rheumatol 25 1 Suppl. 44 (2007) S23-S27
71. Sanchez-Cano D., Callejas-Rubio J.L., and Ortego-Centeno N. Effect of rituximab on refractory Wegener granulomatosis with predominant granulomatous disease. J Clin Rheumatol 14 2 (2008) 92-93
72. Lovric S., Erdbruegger U., Kümpers P., Woywodt A., Koenecke C., Wedemeyer H., et al. Rituximab as rescue therapy in anti-neutrophil cytoplasmatic antibody-associated vasculitis: single centre experience with 15 patients. Nephrol Dial Transplant 6 (Aug 2008) [Epub ahead of print]
73. Roccatello D., Baldovino S., Alpa M., Rossi D., Napoli F., Naretto C., et al. Effects of anti-CD20 monoclonal antibody as a rescue treatment for ANCA-associated idiopathic systemic vasculitis with or without overt renal involvement. Clin Exp Rheumatol 26 3 Suppl. 49 (2008) S67-S71
74. Seo P., Specks U., and Keogh K.A. Efficiacy of rituximab in limited Wegener's granulomatosis with refractory granulomatous manifestations. J Rheumatol 35 10 (2008) 2017-2023
75. Booth A., Jefferson H.J., Ayliffe W., Andrews P.A., and Jayne D.R. Safety and efficacy of TNF-alpha blockade in relapsing vasculitis. Ann Rheum Dis 61 (2002) 559
76. Bartolucci P., Ramanoelina J., Cohen P., Mahr A., Godmer P., Le Hello C., et al. Efficacy of the anti-TNF-alpha antibody infliximab against refractory systemic vasculitides: an open pilot study on 10 patients. Rheumatology 41 10 (2002) 1126-1132
77. Lamprecht P., Voswinkel J., Lilienthal T., Noelle B., Heller M., Gross W.L., et al. Effective ness of TNF-alpha blockade with infliximab in refractory Wegener's granulomatosis. Rheumatology 41 11 (2002) 1303-1307
78. Booth A., Harper L., Hammad T., Bacon P., Griffith M., Levy J., et al. Prospective study of TNF alpha blockade with infliximab in anti-neutrophil cytoplasmatic antibody-associated systemic vasculitis. J Am Soc Nephrol 15 39 (2004) 717-721
79. Schmitt W.H., Hagen E.C., Neumann I., Nowack R., Flores-Suarez L.F., and van der Woude F.J. Treatment of refractory Wegener's granulomatosis with antithymocyte globulin (ATG): an open study in 15 patients. Kidney Int 65 4 (2004) 1440-1448
80. Birck R., Warnatz K., Lorenz H.M., Choi M., Haubitz M., Grunke M., et al. 15-Deoxyspergualin in patients with refractory ANCA-associated systemic vasculitis: a six-month open-label trial to evaluate safety and efficacy. J Am Soc Nephrol 14 2 (2003) 440-447
81. Schmitt W.H., Birck R., Heinzel P.A., Göbel U., Choi M., Warnatz K., et al. Prolonged treatment of refractory Wegener's granulomatosis with 15-deoxyspergualin: an open study in seven patients. Nephrol Dial Transplant 20 6 (2005) 1083-1092
82. Flossmann O., Baslund B., Bruchfeld A., Cohen Taervert J.W., Hall C., Heinzel P., et al. Deoxyspergualin in relapsing and refractory Wegener's granulomatosis. Ann Rheum Dis 19 (Aug 2008) [Epub ahead of print]
83. Stassen P.M., Cohen Tervaert J.W., and Stegeman C.A. Induction of remission in active anti-neutrophil cytoplasmic antibody-associated vasculitis with mycophenolate mofetil in patients who cannot be treated with cyclophosphamide. Ann Rheum Dis 66 6 (2007) 798-802
84. Joy M.S., Hogan S., Jeannette J.C., Falk R.J., and Nachman P.H. A pilot study using mycophenolate mofetil in relapsing or resistant ANCA small vessel vasculitis. Nephrol Dial Transplant 20 12 (2005) 2725-2732
85. Jayne D.J., Davies M.J., Fox C.J., Black C.M., and Lockwood C.M. Treatment of systemic vasculitis with pooled intravenous immunoglobulin. Lancet 337 8750 (1991) 1137-1139
86. Richter C., Schnabel A., Csernok E., Reinhold-Keller E., and Gross W.L. Treatment of Wegener's granulomatosis with intravenous immunoglobulin. Adv Exp Med Biol 336 (1993) 487-489
87. Jayne D.R., and Lockwood C.M.M. Pooled intravenous immunoglobulin in the management of systemic vasculitis. Adv Exp Med Biol 336 (1993) 469-472
88. Jayne D.R., and Lockwood C.M. Intravenous immunoglobulin as sole therapy for systemic vasculitis. Br J Rheumatol 35 11 (1996) 1150-1153
89. Jayne D.R., Chapel H., Adu D., Misbah S., O`Donoghue D., Scott D., et al. Intravenous immunoglobulin for ANCA-associated systemic vasculitis with persistent disease activity. QJM 93 7 (2000) 433-439
90. Gayraud M., Guillevin L., le Toumelin P., Cohen P., Lhote F., Casassus P., et al. Long-term followup of polyarteritis nodosa, microscopic polyangiitis and Churg-Strauss syndrome: analysis of four prospective trials including 278 patients. Arthritis Rheum 44 3 (2001) 666-675
91. Guillevin L., Jarrousse B., Lok C., Lhote F., Jais J.P., Le Thi Huong Du D., et al. Longterm followup after treatment of polyarteritis nodosa and Churg-Strauss angiitis with comparison of steroids, plasma exchange and cyclophosphamide to steroids and plasma exchange. A prospective randomized trial of 71 patients. The Cooperative Study Group for Polyarteritis Nodosa. J Rheumatol 18 4 (1991) 567-574
92. Gayraud M., Guillevin L., Cohen P., Lhote F., Cacoub P., Deblois P., et al. Treatment of good-prognosis polyarteritis nodosa and Churg-Strauss syndrome: comparison of steroids and oral or pulse cyclophosphamide in 25 patients. French Cooperative Study Group for Vasculitides. Br J Rheumatol 36 12 (1997) 1290-1297
93. Cohen P., Pagnoux C., Mahr A., Arene J.P., Mouthon L., Le Guern V., et al. Churg-Strauss syndrome with poor-prognosis factors: a prospective multicenter trial comparing glucocorticoids and six or twelve cyclophosphamide pulses in forty-eight patients. Arthritis Rheum 57 4 (2007) 686-693
94. Guillevin L., Fain O., Lhote F., Jarrousse B., Le Thi Huong B., Bussel A., et al. Lack of superiority of steroids plus plasma exchange to steroids alone in the treatment of polyarteritis nodosa and Churg-Strauss syndrome. A prospective, randomized trial in 78 patients. Arthritis Rheum 35 (1992) 208-215
95. Guillevin L., Lhote F., Cohen P., Jarousse B., Lortholary O., Généreau T., et al. Corticosteroids plus pulse cyclophosphamide and plasma exchanges versus corticosteroids plus pulse cyclophosphamide alone in the treatment of polyarteritis nodosa and Churg-Strauss syndrome patients with factors predicting poor prognosis. A prospective, randomized trial in sixty-two patients. Arthritis Rheum 38 (1995) 1638-1645
96. Ribi C., Cohen P., Pagnoux C., Mahr A., Arene J.P., Lauque D., et al. Treatment of Churg-Strauss syndrome without poor-prognosis factors: a multicenter, prospective, randomized open-label study of seventy-two patients. Arthritis Rheum 58 2 (2008) 586-594
97. Metzler C., Hellmich B., Gause A., Gross W.L., and de Groot K. Churg Strauss syndrome - successful induction of remission with methotrexate and unexpected high cardiac and pulmonary relapse ratio during maintenance treatment. Clin Exp Rheumatol 22 6 Suppl. 36 (2004) S52-S61
98. Tatsis E., Schnabel A., and Gross W.L. Interferon-alpha treatment of four patients with Churg-Strauss syndrome. Ann Intern Med 129 5 (1998) 370-374
99. Metzler C., Lamprecht P., Hellmich B., Reuter M., Arlt A.C., and Gross W.L. Leucoencephalopathy after treatment of Churg-Strauss syndrome with interferon (alpha). Ann Rheum Dis 64 8 (2005) 1242-1243
100. Metzler C., Schnabel A., Gross W.L., and Hellmich B. A phase II study of interferon-alpha for the treatment of refractory Churg-Strauss syndrome. Clin Exp Rheumatol 26 3 Suppl. 49 (2008) S35-S40
101. Arbach O., Gross W.L., and Gause A. Treatment of refractory Churg-Strauss-Syndrome (CSS) by TNF-alpha blockade. Immunobiology 206 5 (2002) 496-501
102. Koukoulaki M., Smith K.G., and Jayne D.R. Rituximab in Churg-Strauss syndrome. Ann Rheum Dis 65 4 (2006) 557-559
103. Hellmich B., Kausch I., Doehn C., Jocham D., Holl-Ulrich K., and Gross W.L. Urinary bladder cancer in Wegener's granulomatosis undergoing immunosuppressive therapy. Arthritis Rheum 43 8 (2000) 1841-1848
104. Talar-Williams C., Hijazi Y.M., Walther M.M., Linehan W.M., Hallahan C.W., Lubensky I., et al. Cyclophosphamide-induced cystitis and bladder cancer in patients with Wegener's granulomatosis. Ann Intern Med 124 (1996) 477-484
105. Knight A., Askling J., Granath F., Sparen P., and Ekbom A. Urinary bladder cancer in Wegener's granulomatosis: risks and relation to cyclophosphamide. Ann Rheum Dis 63 (2004) 1307-1311
106. Charlier C., Henegar C., Launay O., Pagnoux C., Berezne A., Bienvenu B., et al. Risk factors for major infections in Wegner's granulomatosis: analysis of 113 patients. Ann Rheum Dis 2 (Jun 2008) [Epub ahead of print]
107. Ognibene F.P., Shelhamer J.H., Hoffman G.S., Kerr G.S., Reda D., Fauci A.S., et al. Pneumocystis carinii pneumonia: a major complication of immunosuppressive therapy in Wegener's granulomatosis. Am J Respir Crit Care Med 151 (1995) 795-799
108. Godeau B., Mainardi J.L., Roudot-Thoraval F., Hachulla E., Guillevin L., Huong Du L.T., et al. Factors associated with pneumocystis carinii pneumonia in the course of connective tissue disease: report of 34 cases. Ann Rheum Dis 54 (1995) 246-251
109. Birck R., Schmitt W.H., Kaelsch I.A., and van der Woude F.J. Serial ANCA determinations for monitoring disease activity in patients with ANCA-associated vasculitis: systematic review. Am J Kidney Dis 47 (2006) 15-23
110. Rothenberg M., Klion A., Roufosse F., Kahn J., Weller P., Simon H., et al. Treatment of patients with the hypereosinophilic syndrome with mepolizumab. N Engl J Med 358 (2008) 1215-1228